← Back to Search

ICM for Atrial Fibrillation

N/A
Recruiting
Led By Dhanunjaya Lakkireddy
Research Sponsored by Kansas City Heart Rhythm Research Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

Observational, multi-center, retrospective study to evaluate the use of ICM (implantable cardiac monitor) versus traditional, non-ICM (non-implantable cardiac monitor) methods such as ECGs (electrocardiogram), Holter, and mobile cardiac outpatient telemetry (MCOT) units.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
No.of patients with arrhythmia recurrence
No.of patients with redo ablation

Trial Design

2Treatment groups
Experimental Treatment
Group I: Non-ICMExperimental Treatment1 Intervention
Patients with traditional monitoring methods
Group II: ICMExperimental Treatment1 Intervention
Patients who underwent ICM insertion

Find a Location

Who is running the clinical trial?

Kansas City Heart Rhythm Research FoundationLead Sponsor
26 Previous Clinical Trials
9,472 Total Patients Enrolled
13 Trials studying Atrial Fibrillation
1,808 Patients Enrolled for Atrial Fibrillation
Dhanunjaya LakkireddyPrincipal InvestigatorKansas City Heart Rhythm Institute
11 Previous Clinical Trials
6,586 Total Patients Enrolled
6 Trials studying Atrial Fibrillation
726 Patients Enrolled for Atrial Fibrillation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
JAMA CardiologyJournal
Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-risk Population
Reiffel, James A., Atul Verma, Peter R. Kowey, Jonathan L. Halperin, Bernard J. Gersh, Rolf Wachter, Erika Pouliot, Paul D. Ziegler, and for the REVEAL AF Investigators. 2017. “Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-risk Population”. JAMA Cardiology. American Medical Association (AMA). doi:10.1001/jamacardio.2017.3180.
clinicaltrials.govStudy
Dynamic Data-Driven Management of Atrial Fibrillation Using Implantable Cardiac Monitors: The MONITOR-AF Study
2024. "Dynamic Data-Driven Management of Atrial Fibrillation Using Implantable Cardiac Monitors: The MONITOR-AF Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06352060.
All > Kansas City
~1250 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top